vs

Side-by-side financial comparison of Avidity Biosciences, Inc. (RNA) and SB FINANCIAL GROUP, INC. (SBFG). Click either name above to swap in a different company.

SB FINANCIAL GROUP, INC. is the larger business by last-quarter revenue ($16.4M vs $12.5M, roughly 1.3× Avidity Biosciences, Inc.). SB FINANCIAL GROUP, INC. runs the higher net margin — 23.9% vs -1398.3%, a 1422.2% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 6.3%). SB FINANCIAL GROUP, INC. produced more free cash flow last quarter ($21.4M vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 11.8%).

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

SB Financial Group, Inc. is a U.S.-headquartered financial holding company that provides a full suite of personal and commercial banking products and services, including deposit accounts, mortgage and consumer loans, small business financing, and wealth management solutions. It primarily serves retail customers and small to medium-sized enterprises across regional markets in the United States.

RNA vs SBFG — Head-to-Head

Bigger by revenue
SBFG
SBFG
1.3× larger
SBFG
$16.4M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+427.8% gap
RNA
434.0%
6.3%
SBFG
Higher net margin
SBFG
SBFG
1422.2% more per $
SBFG
23.9%
-1398.3%
RNA
More free cash flow
SBFG
SBFG
$178.3M more FCF
SBFG
$21.4M
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
11.8%
SBFG

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
RNA
RNA
SBFG
SBFG
Revenue
$12.5M
$16.4M
Net Profit
$-174.4M
$3.9M
Gross Margin
Operating Margin
-1513.5%
30.3%
Net Margin
-1398.3%
23.9%
Revenue YoY
434.0%
6.3%
Net Profit YoY
-117.0%
7.8%
EPS (diluted)
$-1.27
$0.62

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RNA
RNA
SBFG
SBFG
Q4 25
$16.4M
Q3 25
$12.5M
$16.6M
Q2 25
$3.8M
$17.2M
Q1 25
$1.6M
$15.4M
Q4 24
$3.0M
$15.5M
Q3 24
$2.3M
$14.3M
Q2 24
$2.0M
$14.0M
Q1 24
$3.5M
$13.1M
Net Profit
RNA
RNA
SBFG
SBFG
Q4 25
$3.9M
Q3 25
$-174.4M
$4.0M
Q2 25
$-157.3M
$3.9M
Q1 25
$-115.8M
$2.2M
Q4 24
$-102.3M
$3.6M
Q3 24
$-80.4M
$2.4M
Q2 24
$-70.8M
$3.1M
Q1 24
$-68.9M
$2.4M
Operating Margin
RNA
RNA
SBFG
SBFG
Q4 25
30.3%
Q3 25
-1513.5%
29.9%
Q2 25
-4448.7%
27.5%
Q1 25
-8360.9%
16.8%
Q4 24
-4069.6%
29.3%
Q3 24
-4200.9%
21.7%
Q2 24
-4040.4%
24.0%
Q1 24
-2178.6%
21.7%
Net Margin
RNA
RNA
SBFG
SBFG
Q4 25
23.9%
Q3 25
-1398.3%
24.4%
Q2 25
-4089.3%
22.4%
Q1 25
-7360.0%
14.0%
Q4 24
-3439.5%
23.5%
Q3 24
-3441.7%
16.5%
Q2 24
-3461.8%
22.2%
Q1 24
-1943.4%
18.0%
EPS (diluted)
RNA
RNA
SBFG
SBFG
Q4 25
$0.62
Q3 25
$-1.27
$0.64
Q2 25
$-1.21
$0.60
Q1 25
$-0.90
$0.33
Q4 24
$-0.80
$0.55
Q3 24
$-0.65
$0.35
Q2 24
$-0.65
$0.47
Q1 24
$-0.79
$0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RNA
RNA
SBFG
SBFG
Cash + ST InvestmentsLiquidity on hand
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.9B
$141.2M
Total Assets
$2.1B
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RNA
RNA
SBFG
SBFG
Q4 25
Q3 25
$350.2M
Q2 25
$243.9M
Q1 25
$254.2M
Q4 24
$219.9M
Q3 24
$370.2M
Q2 24
$575.8M
Q1 24
$471.4M
Total Debt
RNA
RNA
SBFG
SBFG
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$19.7M
Q3 24
$19.7M
Q2 24
Q1 24
Stockholders' Equity
RNA
RNA
SBFG
SBFG
Q4 25
$141.2M
Q3 25
$1.9B
$136.9M
Q2 25
$1.2B
$133.6M
Q1 25
$1.3B
$131.5M
Q4 24
$1.4B
$127.5M
Q3 24
$1.5B
$132.8M
Q2 24
$1.2B
$125.5M
Q1 24
$830.9M
$123.7M
Total Assets
RNA
RNA
SBFG
SBFG
Q4 25
$1.5B
Q3 25
$2.1B
$1.5B
Q2 25
$1.4B
$1.5B
Q1 25
$1.5B
$1.5B
Q4 24
$1.6B
$1.4B
Q3 24
$1.6B
$1.4B
Q2 24
$1.3B
Q1 24
$951.5M
Debt / Equity
RNA
RNA
SBFG
SBFG
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.15×
Q3 24
0.15×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RNA
RNA
SBFG
SBFG
Operating Cash FlowLast quarter
$-156.2M
$24.0M
Free Cash FlowOCF − Capex
$-156.9M
$21.4M
FCF MarginFCF / Revenue
-1257.6%
130.6%
Capex IntensityCapex / Revenue
5.7%
15.8%
Cash ConversionOCF / Net Profit
6.14×
TTM Free Cash FlowTrailing 4 quarters
$-592.3M
$35.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RNA
RNA
SBFG
SBFG
Q4 25
$24.0M
Q3 25
$-156.2M
$12.7M
Q2 25
$-199.7M
$-3.6M
Q1 25
$-124.8M
$6.7M
Q4 24
$-99.9M
$9.5M
Q3 24
$-65.6M
$3.6M
Q2 24
$-65.0M
$-434.0K
Q1 24
$-70.4M
$308.0K
Free Cash Flow
RNA
RNA
SBFG
SBFG
Q4 25
$21.4M
Q3 25
$-156.9M
$12.2M
Q2 25
$-203.0M
$-4.2M
Q1 25
$-128.6M
$5.8M
Q4 24
$-103.8M
$8.2M
Q3 24
$-67.3M
$3.2M
Q2 24
$-65.5M
$-833.0K
Q1 24
$-71.3M
$149.0K
FCF Margin
RNA
RNA
SBFG
SBFG
Q4 25
130.6%
Q3 25
-1257.6%
73.8%
Q2 25
-5277.1%
-24.2%
Q1 25
-8174.3%
37.6%
Q4 24
-3491.0%
53.2%
Q3 24
-2881.8%
22.6%
Q2 24
-3204.6%
-5.9%
Q1 24
-2012.3%
1.1%
Capex Intensity
RNA
RNA
SBFG
SBFG
Q4 25
15.8%
Q3 25
5.7%
2.7%
Q2 25
86.9%
3.1%
Q1 25
238.6%
6.0%
Q4 24
131.7%
8.0%
Q3 24
72.9%
2.7%
Q2 24
26.0%
2.8%
Q1 24
25.8%
1.2%
Cash Conversion
RNA
RNA
SBFG
SBFG
Q4 25
6.14×
Q3 25
3.14×
Q2 25
-0.94×
Q1 25
3.11×
Q4 24
2.60×
Q3 24
1.54×
Q2 24
-0.14×
Q1 24
0.13×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons